Drosophila as a tool for personalized medicine: A primer

Personalized Medicine

Volumn 7, Issue 6, 2010, Pages 621-632

  Kasai, Yumi ^a   Cagan, Ross ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

cancer; diabetes; Drosophila; heart disease; multigenic

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; VANDETANIB;

ANIMAL CELL CULTURE; CANCER MODEL; DIABETES MELLITUS; DISEASE MODEL; DNA MODIFICATION; DROSOPHILA; DRUG DESIGN; FRAGILE X SYNDROME; GENE; GENE EXPRESSION; GENE MAPPING; GENETIC ASSOCIATION; GENOMICS; GLIOMA; HEART DISEASE; HUMAN; IN VIVO STUDY; MEDICAL RESEARCH; MEDICINE; NEOPLASM; NEUROFIBROMATOSIS; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

EID: 78649990389     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.65     Document Type: Review

References (85)

1. Dasgupta R, Perrimon N: Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer research. Oncogene 23(51), 8359-8365 (2004).
2. Venken KJ, Bellen HJ: Transgenesis upgrades for Drosophila melanogaster. Development 134(20), 3571-3584 (2007).
3. Venken KJ, Carlson JW, Schulze KL et al.: Versatile P[acman] BAC libraries for transgenesis studies in Drosophila melanogaster. Nat. Methods 6(6), 431-434 (2009).
4. Casanova ML, Larcher F, Casanova B et al.: A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin. Carcinogenesis Cancer Res. 62(12), 3402-3407 (2002).
5. Janes PW, Daly RJ, deFazio A, Sutherland RL: Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9(12), 3601-3608 (1994).
6. Martinez-Lacaci I, Kannan S, De Santis M et al.: RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells. Int. J. Cancer 88(1), 44-52 (2000).
7. Lesokhin AM, Yu SY, Katz J, Baker NE: Several levels of EGF receptor signaling during photoreceptor specifcation in wild-type, Ellipse, and null mutant Drosophila Dev. Biol. 205(1), 129-144 (1999).
8. Brand AH, Perrimon N: Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118(2), 401-415 (1993).
9. Kim K, Lee YS, Harris D, Nakahara K, Carthew RW: The RNAi pathway initiated by Dicer-2 in Drosophila. Cold Spring Harb. Symp. Quant. Biol. 71, 39-44 (2006).
10. Mohr S, Bakal C, Perrimon N: Genomic screening with RNAi: results and challenges. Annu. Rev. Biochem. 79, 37-64 (2010).
11. DasGupta R, Kaykas A, Moon RT, Perrimon N: Functional genomic analysis of the Wnt-wingless signaling pathway. Science 308(5723), 826-833 (2005).
12. Lum L, Yao S, Mozer B et al.: Identifcation of Hedgehog pathway components by RNAi in Drosophila cultured cells. Science 299(5615), 2039-2045 (2003).
13. Nybakken K, Vokes SA, Lin TY, McMahon AP, Perrimon N: A genome-wide RNA interference screen in Drosophila melanogaster cells for new components of the Hh signaling pathway. Nat. Genet. 37(12), 1323-1332 (2005).
14. Cully M, Genevet A, Warne P et al.: A role for p38 stress-activated protein kinase in regulation of cell growth via TORC1. Mol. Cell. Biol. 30(2), 481-495.
15. Friedman A, Perrimon N: A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling. Nature 444(7116), 230-234 (2006).
16. Bryant PJ, Levinson P: Intrinsic growth control in the imaginal primordia of Drosophila, and the autonomous action of a lethal mutation causing overgrowth. Dev. Biol. 107(2), 355-363 (1985).
17. Woods DF, Bryant PJ: The discs-large tumor suppressor gene of Drosophila encodes a guanylate kinase homolog localized at septate junctions. Cell 66(3), 451-464 (1991).
18. Read RD, Goodfellow PJ, Mardis ER et al.: A Drosophila model of multiple endocrine neoplasia type 2. Genetics 171(3), 1057-1081 (2005).
19. Vidal M, Warner S, Read R, Cagan RL: Differing Src signaling levels have distinct outcomes in Drosophila Cancer Res. 67(21), 10278-10285 (2007).
20. Acharya CR, Hsu DS, Anders CK et al.: Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 299(13), 1574-1587 (2008).
21. Biscardi JS, Maa MC, Tice DA et al.: c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 274(12), 8335-8343 (1999).
22. Bougeret C, Jiang S, Keydar I, Avraham H: Functional analysis of Csk and CHK kinases in breast Cancer Cells. J. Biol. Chem. 276(36), 33711-33720 (2001).
23. Dimri M, Naramura M, Duan L et al.: Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res. 67(9), 4164-4172 (2007).
24. Hitosugi T, Sasaki K, Sato M, Suzuki Y, Umezawa Y: Epidermal growth factor directs sex-specifc steroid signaling through Src activation. J. Biol. Chem. 282(14), 10697-10706 (2007).
25. Ishizawar RC, Miyake T, Parsons SJ: c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 26(24), 3503-3510 (2007).
26. Moiseeva EP, Heukers R, Manson MM: EGFR and Src are involved in indole-3-carbinol-induced death and cell cycle arrest of human breast cancer cells. Carcinogenesis 28(2), 435-445 (2007).
27. Tan M, Li P, Klos KS et al.: ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res. 65(5), 1858-1867 (2005).
28. Long W, Yi P, Amazit L et al.: SRC-3d4 mediates the interaction of EGFR with FAK to promote cell migration. Mol. Cell 37(3), 321-332 (2010).
29. Ricono JM, Huang M, Barnes LA et al.: Specifc cross-talk between epidermal growth factor receptor and integrin avb5 promotes carcinoma cell invasion and metastasis. Cancer Res. 69(4), 1383-1391 (2009).
30. Hiscox S, Morgan L, Green TP et al.: Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 97(3), 263-274 (2006).
31. Ishizawar R, Parsons SJ: c-Src and cooperating partners in human cancer. Cancer Cell 6(3), 209-214 (2004).
32. Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R: Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett. 543(1-3), 76-80 (2003).
33. Mao W, Irby R, Coppola D et al.: Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15(25), 3083-3090 (1997). (Pubitemid 28043487)
34. Ferres-Marco D, Gutierrez-Garcia I, Vallejo DM et al.: Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing. Nature 439(7075), 430-436 (2006).
35. Brand AH, Manoukian AS, Perrimon N: Ectopic expression in Drosophila. Methods Cell Biol. 44, 635-654 (1994).
36. Toba G, Ohsako T, Miyata N et al.: The gene search system. A method for effcient detection and rapid molecular identifcation of genes in Drosophila melanogaster. Genetics 151(2), 725-737 (1999).
37. McGuire SE, Roman G, Davis RL: Gene expression systems in Drosophila: a synthesis of time and space. Trends Genet. 20(8), 384-391 (2004).
38. Bolos V, Blanco M, Medina V et al.: Notch signalling in cancer stem cells. Clin. Transl. Oncol. 11(1), 11-19 (2009).
39. Farnie G, Clarke RB: Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev. 3(2), 169-175 (2007).
40. Panelos J, Massi D: Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol. Ther. 8(21), 1986-1993 (2009).
41. Moberg KH, Schelble S, Burdick SK, Hariharan IK: Mutations in erupted, the Drosophila ortholog of mammalian tumor susceptibility gene 101, elicit non-cell-autonomous overgrowth. Dev. Cell. 9(5), 699-710 (2005).
42. Thompson BJ, Mathieu J, Sung HH et al.: Tumor suppressor properties of the ESCRT-II complex component Vps25 in Drosophila. Dev. Cell. 9(5), 711-720 (2005).
43. Brumby AM, Richardson HE: Scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in Drosophila. EMBO J. 22(21), 5769-5779 (2003).
44. Lehmann M, Siegmund T, Lintermann KG, Korge G: The pipsqueak protein of Drosophila melanogaster binds to GAGA sequences through a novel DNA-binding domain. J. Biol. Chem. 273(43), 28504-28509 (1998).
45. Giniger E, Tietje K, Jan LY, Jan YN: lola encodes a putative transcription factor required for axon growth and guidance in Drosophila. Development 120(6), 1385-1398 (1994).
46. Mishra K, Chopra VS, Srinivasan A, Mishra RK: Trl-GAGA directly interacts with lola like and both are part of the repressive complex of Polycomb group of genes. Mech. Dev. 120(6), 681-689 (2003).
47. Read RD, Cavenee WK, Furnari FB, Thomas JB: A Drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet. 5(2), E1000374 (2009).
48. Ocorr K, Perrin L, Lim HY et al.: Genetic control of heart function and aging in Drosophila. Trends Cardiovasc. Med. 17(5), 177-182 (2007).
49. Wessells RJ, Fitzgerald E, Cypser JR, Tatar M, Bodmer R: Insulin regulation of heart function in aging fruit fies. Nat. Genet. 36(12), 1275-1281 (2004).
50. Bier E, Bodmer R: Drosophila, an emerging model for cardiac disease. Gene 342(1), 1-11 (2004).
51. Bodmer R, Venkatesh T V, Heart development in Drosophila and vertebrates: conservation of molecular mechanisms. Dev. Genet. 22(3), 181-186 (1998).
52. Alayari NN, Vogler G, Taghli-Lamallem O et al.: Fluorescent labeling of Drosophila heart structures. J. Vis. Exp. 32, pii 1423 (2009).
53. Ocorr K, Reeves NL, Wessells RJ et al.: KCNQ potassium channel mutations cause cardiac arrhythmias in Drosophila that mimic the effects of aging. Proc. Natl Acad. Sci. USA 104(10), 3943-3948 (2007).
54. Wessells RJ, Bodmer R: Age-related cardiac deterioration: insights from Drosophila. Front. Biosci. 12, 39-48 (2007). (Pubitemid 46852826)
55. Kim SO, Avraham S, Jiang S et al.: Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors. Cancer 101(5), 1018-1027 (2004).
56. Rulifson EJ, Kim SK, Nusse R: Ablation of insulin-producing neurons in fies: growth and diabetic phenotypes. Science 296(5570), 1118-1120 (2002).
57. Khosla S, Patel VM, Hay ID et al.: Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J. Clin. Invest. 87(5), 1691-1699 (1991).
58. Mulligan LM, Kwok JB, Healey CS et al.: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363(6428), 458-460 (1993).
59. Massoll N, Mazzaferri EL: Diagnosis and management of medullary thyroid carcinoma. Clin. Lab. Med. 24(1), 49-83 (2004).
60. Carlomagno F, Vitagliano D, Guida T et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, effciently blocks oncogenic RET kinases. Cancer Res. 62(24), 7284-7290 (2002).
61. Wells SA Jr, Gosnell JE, Gagel RF et al.: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28(5), 767-772 (2010).
62. Chang S, Bray SM, Li Z et al.: Identifcation of small molecules rescuing Fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4(4), 256-263 (2008).
63. Hou L, Antion MD, Hu D et al.: Dynamic translational and proteasomal regulation of Fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51(4), 441-454 (2006).
64. Antar LN, Afroz R, Dictenberg JB, Carroll RC, Bassell GJ: Metabotropic glutamate receptor activation regulates Fragile X mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J. Neurosci. 24(11), 2648-2655 (2004).
65. Weiler IJ, Irwin SA, Klintsova AY et al.: Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc. Natl Acad. Sci. USA 94(10), 5395-5400 (1997).
66. Cooper AA, Gitler AD, Cashikar A et al.: A-synuclein blocks ER-Golgi traffc and Rab1 rescues neuron loss in Parkinson's models. Science 313(5785), 324-328 (2006).
67. Clark IE, Dodson MW, Jiang C et al.: Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441(7097), 1162-1166 (2006).
68. Park J, Lee SB, Lee S et al.: Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441(7097), 1157-1161 (2006).
69. Chen L, Feany MB: A-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8(5), 657-663 (2005).
70. Hanai S, Kanai M, Ohashi S et al.: Loss of poly(ADP-ribose) glycohydrolase causes progressive neurodegeneration in Drosophila melanogaster. Proc. Natl Acad. Sci. USA 101(1), 82-86 (2004).
71. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B: Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37(6), 911-924 (2003).
72. Auluck PK, Bonini NM: Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8(11), 1185-1186 (2002).
73. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM: Chaperone suppression of a-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295(5556), 865-868 (2002).
74. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B et al.: Identifcation of genes that modify ataxin-1-induced neurodegeneration. Nature 408(6808), 101-106 (2000).
75. Feany MB, Bender WW: A Drosophila model of Parkinson's disease. Nature 404(6776), 394-398 (2000).
76. Romero E, Cha GH, Verstreken P et al.: Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 57(1), 27-40 (2008).
77. Sarkar S, Perlstein EO, Imarisio S et al.: Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 3(6), 331-338 (2007).
78. Steffan JS, Agrawal N, Pallos J et al.: SUMO modifcation of Huntingtin and Huntington's disease pathology. Science 304(5667), 100-104 (2004).
79. Gunawardena S, Her LS, Brusch RG et al.: Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40(1), 25-40 (2003).
80. Steffan JS, Bodai L, Pallos J et al.: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413(6857), 739-743 (2001).
81. Kazemi-Esfarjani P, Benzer S: Genetic suppression of polyglutamine toxicity in Drosophila. Science 287(5459), 1837-1840 (2000).
82. Jackson GR, Salecker I, Dong X et al.: Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21(3), 633-642 (1998).
83. Chen HK, P. Fernandez-Funez, Acevedo SF et al.: Interaction of Akt-phosphorylated ataxin-1 with 14-13-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113(4), 457-468 (2003).
84. Warrick JM, Paulson HL, Gray-Board GL et al.: Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93(6), 939-949 (1998).
85. Vidal M, Wells S, Ryan A, Cagan R: ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 65(9), 3538-3541 (2005).